1980s

Documents dated 1980–1989.

Page 5 of 6 — 597 documents
Title / Summary Year AR226 Docket Hash ID Pages
The document summarizes biodegradation studies on a mixture containing perfluorooctanesulfonate (PFOS) produced by 3M, indicating that while the majority of product components are readily biodegradable, the data does not accurately reflect the biodegradation potential of the fluorochemical component. 1981 AR226-0801 68Y6wexj7rGdQjg0mxjb9RGg 18
The document details an acute toxicity test conducted on fathead minnows (Pimephales promelas) using a mixture containing 0.73% perfluorooctanesulfonate (PFOS) and various other components, following a flow-through method over a 96-hour exposure period. 1981 AR226-0803 x51x71Drkv3xgOxYnwRDYNN7y 14
The document details a toxicity test of a mixture containing 0.73% PFOS, conducted on the aquatic plant species Selenastrum capricomutum, using methods from USEPA and ASTM to assess algal cell counts and dry weights over a 96-hour exposure period. 1981 AR226-0805 wKB1wN2rnbvp79QzZeVygOYEE 10
The document reports on a two-year oral toxicity and carcinogenicity study of fluorochemical FM-3924, conducted by Riker Laboratories, Inc. for 3M Company, focusing on its effects in rats from April 1981 to May 1983. 1981 AR226-0260 KM1gv4zVRjMpvMw34jm1Ny92 325
This document details an oral rangefinder study conducted by Riker Laboratories, sponsored by 3M, to determine the upper dose level of T-2999CoC for a subsequent teratology study in pregnant rabbits. 1981 AR226-0275 99407jGgKqXqLqRke08ojzMY6 10
The document reports on an oral teratology study of T-2999CoC, sponsored by 3M, which found that while the compound was not teratogenic in pregnant rabbits, it caused embryotoxicity at the highest dose of 15 mg/kg/day, leading to increased abortions and low neonatal survival. 1981 AR226-0276 X11mX9gM63dMZoxXN2knvbXg 37
The document details the analytical results of four corn oil samples containing varying concentrations of FM-3924, indicating that while all samples were within 10% of the target concentration, the solubility of FM-3924 was low and crystallization could pose issues for a rat feeding study. 1981 AR226-0278 DGVndJEpRegr8bQ2GRaVb74EO 1
The document reports on a teratology study conducted by Riker Laboratories to evaluate the effects of T-2999CoC on rat lenses during organogenesis, concluding that lens abnormalities observed were artifacts rather than compound-related effects, with no significant differences among dose groups. 1981 AR226-0282 GmroRww1vG9OzJ0jYRnE7mxkY 21
This is a teratology study report (Experiment No. 0681TR0362) conducted by Riker Laboratories Inc. on the effects of T-2999CoC in two strains of rats, focusing on the histological appearance of fetal lenses following oral dosing during gestation. 1981 AR226-0283 B5rJXQvjpQgQeB9b0k6RRy2EL 48
The document reports on the analytical results of four corn oil samples containing varying concentrations of FM-3924, indicating that while the samples showed good reproducibility, the solubility of FM-3924 was low and crystallization could pose issues for a rat feeding study. 1981 AR226-0285 0qQqNQb6gg3kJejKLObZY6G4R 1
The memo from K. G. Lamprecht discusses the misinterpretation of a fetal rat lens artifact as a teratogenic change in Riker Experiments involving developmental eye abnormalities, clarifying that the observed changes were due to lens vesicle remnants and not actual teratogenic effects. 1981 AR226-0287 QXdd0g8Ym0Jx8X1y09056wZgE 3
The document reports on a biodegradation test conducted by 3M Company on a mixture containing perfluorooctanesulfonate (PFOS), revealing high biochemical oxygen demand (BOD) values but lacking reliable conclusions due to insufficient characterization of the test substance and methodology. 1981 AR226-0898 4Jve4de33a9q84X88MweMEJ0Q 9
The document reports on an acute toxicity test of a PFOS-containing mixture (FC-3041) on fathead minnows (Pimephales promelas), indicating that the test was conducted in 1981 with specific conditions and concentrations, but the toxicity data may not accurately reflect the fluorochemical component due to impurities. 1981 AR226-0901 44NpqBrNMj0J6wL9OevygE7va 4
The document reports on an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Daphnia magna, conducted by Rand McNeilly in 1981, with specific details about the test conditions and composition of the test substance. 1981 AR226-0902 4abbrzrkRVoBZkD0vB8MzKdGQ 5
The document reports on an activated sludge respiration inhibition test for a mixture containing 6% PFOS, conducted by 3M, which found no inhibition of activated sludge respiration at a concentration of 1000 mg/L. 1981 AR226-0903 aDLxGv0az9mGokn0yvJLnYkOy 4
The memo from U. G. Lamprecht discusses the misinterpretation of a fetal rat lens artifact as a teratogenic effect in Riker Experiments Nos. 0680TR0008 and 0680TR0010, detailing the nature of the observed lens changes and clarifying that they were not indicative of developmental abnormalities. 1981 AR226-0329 da38KbZpxGy4ywj2e45Xxx9a6 3
The document details a toxicity study of N-ethylperfluorooctane sulfonamidoethanol (N-EtFOSE Alcohol) on freshwater green algae (Selenastrum capricomutum), indicating that the limited water solubility of the substance hindered a definitive determination of its aquatic toxicity. 1981 AR226-0361 LpoepznzpzrdEJXZ42NraGR77 14
The document is a DuPont report on the water solubility of Telomer Alcohol (C8F17CH2CH2OH), conducted under OECD guidelines, as part of the Telomer Research Program. 1981 AR226-1287 2NBm5pZowvveaOanMneLgYDja 17
The document is a report by DuPont detailing the aqueous stability of 8-2 Telomer B Alcohol as a function of pH, conducted under the Telomers Research Program sponsored by The Rand Corporation. 1981 AR226-1290 B8eJpE0DMakLqYNkLRYJOwaYX 31
The document discusses a study by 3-M indicating that ammonium perfluorooctanoate (C-8 compound) used in Teflon manufacture causes eye scarring in rat fetuses following maternal exposure, prompting concerns about potential risks for female employees at Parkersburg and other locations, while questioning the study's validity. 1981 AR226-1307 rBn1JNQpQppZ0LN26vOdjod30 2
Du Pont reassigned about 50 women workers at its Parkersburg, West Virginia plant after 3M reported that the chemical FC-143, linked to birth defects in rats, may pose risks to employees of childbearing age. 1981 AR226-1328 a1JVk5Z6vpMeY05a7anOnxbge 1
A preliminary study indicated that the chemical FC-1-43, used at the Du Pont Company plant, may cause birth defects, leading to the transfer of about 50 women workers to new jobs while additional tests are planned. 1981 AR226-1329 zoD46Br531VqDmzmnnMn09p80 1
This letter from E.I. du Pont de Nemours & Company informs the West Virginia Division of Water Resources about toxicity information regarding ammonium perfluorooctanoate (FC-143), a surfactant used in fluoropolymer resin manufacturing, which has shown potential reproductive toxicity in preliminary animal studies conducted by 3M, prompting Du Pont to reassign female employees of childbearing capability to 1981 AR226-1330 JZRDpNOOday30D8kd6zaa68e 1
The document reports that a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA) tested at a concentration of 1000 mg/L showed no acute inhibitory effect on activated sludge respiration, indicating that FC-127 is not expected to inhibit the activity of activated sludge, although the testing methodology lacks proper documentation and characterization. 1981 AR226-0393 QXp9z4b2Y5YBKq9o7vVEbR4v8 4
The document reports that the 96-hour LC50 for the fish species Pimephales promelas exposed to a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA) was determined to be 863 mg/L, based on testing conducted by 3M Company, although the toxicity results may not accurately reflect the test substance due to the presence 1981 AR226-0394 ppkXGxZxnkxnDb1rYYJk1Z7Dk 5
The document is an amendment to a two-year oral toxicity and carcinogenicity study of fluorochemical FC-143 conducted by Riker Laboratories, Inc. and 3M Company, correcting a typographical error in the titles of clinical chemistry value tables without affecting the interpretation of the data. 1981 AR226-0437 QRQZQ9vN44qDrnZe80j9DNrL 299
The document details a two-year oral toxicity and carcinogenicity study of fluorochemical FC-143 conducted on rats by Riker Laboratories, Inc. for 3M Company, spanning from April 1981 to May 1983. 1981 AR226-0440 91QXxJYZGG7L2GEZ5KrZkjkR7 314
The document describes an oral rangefinder study conducted by 3M Commercial Chemical Division to determine the upper dose level of T-3141CoC for a subsequent teratology study in pregnant rabbits, detailing the methodology and dosing regimen used. 1981 AR226-0464 6BEvrBVbLaXGqLyRRK5ne3zbR 8
The document reports on an oral teratology study of T-2998CoC conducted by Riker Laboratories, sponsored by 3M, which found that the compound was not teratogenic in pregnant rats, although it caused maternal toxicity at the highest dose of 150 mg/kg/day. 1981 AR226-0463 mqjL6kr3VKwE2x6pxekqDykB0 40
The internal correspondence discusses the results of health evaluations conducted in 1981 at the Chemolite plant, highlighting significant abnormalities among employees, including elevated blood pressure and cholesterol levels, which may indicate potential health risks related to exposure to perfluorinated compounds. 1981 AR226-0481 XREL516bj2qxz8bypE4982NR4 3
The document reports the calculation of the octanol/water partition coefficient for perfluorooctanoic acid, ammonium salt (FC-143), conducted by 3M Company, indicating a logP0w of approximately -0.9, suggesting a low tendency for the compound to partition into octanol. 1981 AR226-0493 dmqj5ODDnK419gV2DX1XDqkQ 2
This document details a 1981 acute static toxicity study of perfluorooctanoic acid ammonium salt (PFOA ammonium salt) on the aquatic plant species Selenastrum capricornutum, conducted by the USEPA, which involved various test concentrations and analytical monitoring of algal cell counts and weights. 1981 AR226-0506 OBjMwO09x1qd4rQqg0OJndNw 20
The document contains questions and concerns from the public directed at DuPont regarding the safety and health risks associated with C-8 (PFOA) in drinking water, including inquiries about the company's intentions to stop its use, the long-term health effects, and the impact on property values. 1981 AR226-1689 VVZ4M8QGx6wb87rxggxygqkp 2
The document describes a study conducted by researchers from 3M Company that utilized a gas chromatographic technique to analyze the biotransformation of 1H,1H,2H,2H-perfluorodecanol in adult male rats, identifying perfluorooctanoate as a metabolite and suggesting a defluorination process during metabolism. 1981 AR226-1440 8KVZdYoJDOR401nkYv890Kwy 8
The memo from E. I. du Pont de Nemours & Company discusses the potential risks of FC-143 (Ammonium perfluorooctanoate) based on a 3M pilot study that showed it caused abnormal eye lenses in rat fetuses, recommending the removal of women of childbearing capacity from exposure to FC-143 if blood levels exceed 0.4 ppm. 1981 AR226-1494 mmz20domqb1nED2BVMzYY0pkb 3
This document is an analytical report from DuPont detailing the analysis of 27 blood samples for perfluorooctanoate (PFOA) using gas chromatography, including a comparison of results from different analytical methods. 1981 AR226-1561 2OpVqEYqgqXK5oBoqbYd8Nr 2
The document outlines plans for communication and employee reassignment regarding potential exposure to ammonium perfluorooctanoate (C-8) at various production sites, noting blood levels of C-8 in employees and comparing them to background levels, while indicating that some employees will be removed from exposure and others will undergo additional testing. 1981 AR226-1562 dQ9brVzYqqmLvr8B6K3KbpGaq 2
The document outlines a blood sampling program for employees exposed to C-8 (perfluorooctanoic acid, PFOA) to analyze organic fluorine levels and assess the elimination rate of C-8 from the body, specifically targeting female employees who have worked with TEFLON. 1981 AR226-1563 oK7RKYxbDkLnzEXmQjXxnOE 1
The document discusses the lack of direct correlation between airborne C-8 (PFOA) concentrations and organic fluorine levels in blood samples, indicating that C-8 accumulates in the blood over time, with specific blood levels observed in monomer operators reflecting prolonged exposure rather than immediate elimination. 1981 AR226-1564 e7QJ6J5MXxDZ6Oe2V0XVbVVoq 2
This memo from DuPont discusses a change in the analytical test method for measuring perfluorooctanoic acid (C-8) in blood samples of personnel, indicating that the new gas chromatography method yields results approximately 282% higher than the previous bomb analysis method. 1981 AR226-1565 YrGZr8B5w48Rw9YgODYg2b59y 1
The document discusses DuPont's ongoing program related to Ammonium Perfluorooctanoate (FC-143), highlighting concerns about potential health effects on female employees, including blood analysis for exposure, a planned inhalation teratology study in rats, and the consideration of further epidemiological studies. 1981 AR226-1566 mbqyEKyNgMV9X78rQGoMM28D4 6
The document discusses ongoing blood level testing for C-8 (perfluorooctanoic acid, PFOA) among exposed employees and controls, noting that controls have shown non-detectable levels, while an animal study has been initiated to determine a "no-effect" level in rats. 1981 AR226-1568 GKVrJBMp24L4LG2BexpxkoBDx 1
The memo discusses the potential risks of FC-143 (Ammonium perfluorooctanoate) based on a pilot study by 3M that linked it to abnormal eye lenses in rat fetuses, recommending the removal of women of childbearing capacity from exposure to FC-143 if blood levels exceed 0.4 ppm, while noting that recent measurements indicate background levels in Wilmington office workers 1981 AR226-1569 5bOJdR7g8b9oNQv4Rprn8DJND 3
This document reports the analysis of 48 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision, and quantitation limits of the results. 1981 AR226-1570 nmQDyJXGqMbJvK8wQa0mGQGX8 4
The document reports the analysis of 48 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, analytical methods, and precision of the measurements. 1981 AR226-1571 4vpdE0RVDZKma323Xonrx9VEN 3
The document reports the analysis of nine blood samples for perfluorooctanoate (PFOA) conducted by DuPont's Haskell Laboratory, detailing the results, methodology, and precision of the gas chromatographic method used. 1981 AR226-1573 DMQqpXr8J7wxbVO0vj9D66MZM 2
The document reports the analysis of 27 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, analytical methods, and precision of the measurements. 1981 AR226-1574 6xzJJL0Z3NxYg9Z4kpMkLKo1 3
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, methodology, and precision of the gas chromatographic method used for quantification. 1981 AR226-1575 pBr4yRaKy81j5yYBN97ap2ZZB 2
This document reports the analysis of 14 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the methodology, precision, and quantitation limits of the results. 1981 AR226-1576 QMEyNZ3wamGKmdX3opBmkdOkE 2
The document details the analysis of 18 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, reporting results with a lower limit of quantitation of 0.01 ppm PFOA and a detection limit of approximately 0.004 ppm. 1981 AR226-1577 6B7B0YRYGByEJR9Zmy77np4Y3 2
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results and methodology used, including a gas chromatographic method with specific quantitation limits. 1981 AR226-1578 z42Dk71ygyNQdoj3OVaLv4Ga 4
This document reports the analysis of 16 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision of results, and providing concentration data for each sample. 1981 AR226-1579 emjkz9O2ykJkJQ2jvqXVZonEE 2
This document reports the analysis of five blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the results and methodology used, including a gas chromatographic method with specific detection limits. 1981 AR226-1581 ZnXezBrmRMBjpDERezmRZmeZd 2
This document reports the analysis of five blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, indicating varying concentrations with a detection limit of approximately 0.004 ppm. 1981 AR226-1580 4v1Mr53kQp0OvagBB2BGKLO1V 2
The document outlines a revised voluntary program for monitoring blood levels of organic fluorine (measured as C-8, which refers to PFOA) among employees involved in the production of TEFLON Polymers and Copolymers during 1981 and 1982. 1981 AR226-1582 152xqq4Y59M6mOakpLELL1b5K 3
This document reports the analysis of six blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the concentrations found and the methods used for quantification. 1981 AR226-1584 6ybyz98EYE0wQGEmq1be9JKE 2
The document details the analysis of 11 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, reporting results with a lower limit of quantitation of 0.01 ppm PFOA and a detection limit of approximately 0.004 ppm. 1981 AR226-1583 kDmQY4OjnDd03bOdG3qZXYY0J 2
The document reports the analysis of 21 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the results and methodology used, with a detection limit of 0.004 ppm. 1981 AR226-1585 V3yo5GaRNZ4XQM63YjEeY9aGo 2
This document reports the analysis of 36 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results and methodology used, including a gas chromatographic method with specific detection limits. 1981 AR226-1586 qm0JwExpKRMEGXbqBy3jMX9Qn 3
This document reports the analysis of 35 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, methodology, and precision of the measurements. 1981 AR226-1587 NE8J2nNqzpNe5YmnM8pVedqRR 3
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, indicating that the samples tested showed no detectable levels of PFOA. 1981 AR226-1588 B8KyDR0RGydM8EEz4rQ73L794 2
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, revealing specific concentration levels of PFOA in the samples using a gas chromatographic method. 1981 AR226-1590 dQzb5qBZjReoVypEG4d0yk6YR 2
This document reports the analysis of 21 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision of results, and concentration levels found in the samples. 1981 AR226-1589 NeY3y0nVrq0yDJ9VmpEM2jokV 4
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours & Company, detailing the results and methodology used, including a gas chromatographic method with a detection limit of 0.004 ppm. 1981 AR226-1591 qd4Qx1d20NJ64RL6DKLQv7gX5 2
The document reports the analysis of a blood sample for perfluorooctanoate (PFOA) conducted by DuPont, revealing a concentration of 0.17 ppm F, with details on the analytical method and precision. 1981 AR226-1592 mBnjeGNzZLqRazo6B4K8RNzOg 1
The document outlines the expansion of a voluntary blood sampling program for C-8 (PFOA) among employees in the Fluoropolymers Division, mentions ongoing embryotoxic testing at Haskell Laboratories, and describes an increased air monitoring program to assess exposure levels. 1981 AR226-1593 ZJnpK87dMX5dMRn70L27bbok0 8
The document outlines plans for additional blood sampling of individuals exposed to C-8 (PFOA) in a TEFLON production context, scheduled to be completed within four weeks. 1981 AR226-1594 Z4GGk31kLbex14YkxXweORvGO 2
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, detailing the results and methodology used, with concentrations found ranging from 0.043 to 0.33 ppm. 1981 AR226-1595 e7aEjj3B5pD55K08dNvdbxk0m 2
The document details an aquatic toxicity test of N-ethylperfluorooctane sulfonamidoethanol (N-EtFOSE Alcohol) on freshwater green algae (Selenastrum capricomutum), noting that the limited water solubility of the substance hindered a definitive determination of its toxicity. 1981 AR226-0361 o9570VvmDg36YDbOawE88BL37 14
The document reports on a study conducted by 3M Company assessing the activated sludge respiration inhibition of a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA), indicating no acute inhibitory effect at a concentration of 1000 mg/L, although the results may not accurately reflect the toxicity of the test substance due to the presence of organic solvents. 1981 AR226-0393 nNbXkq1VZkN42JmxLdzQM8k7a 4
The document reports that the 96-hour LC50 for the fish species Pimephales promelas exposed to a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA) was determined to be 863 mg/L, as submitted by 3M Company, although the toxicity results may not accurately reflect the test substance due to the presence of organic 1981 AR226-0394 zQYN1E95KwJE2xJ4noVw39VK7 5
This document is an amendment to a two-year oral toxicity and carcinogenicity study of fluorochemical FC-143 in rats conducted by Riker Laboratories, Inc. for 3M Company, correcting typographical errors in the presentation of clinical chemistry values without altering the interpretation of the data. 1981 AR226-0437 zoMaLQ7Np3451vLBonx06JLQ3 299
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours Company, detailing the concentrations found in various samples collected in July 1981. 1981 AR226-1596 O3pnE376E2BL0RKoBw3ZY7K6p 3
The document presents analytical results of FC-143 (Ammonium Perfluorooctanoate) levels in blood samples from individuals associated with polymer products at Chambers Works, showing a range of concentrations from 0 to 0.250, with an overall mean of 0.049. 1981 AR226-1597 Dz258bMxqXn2OYzDrRdgJyBB 1
The document outlines the results of a biological monitoring program for FC-143 (ammonium perfluorooctanoate) in blood samples from employees, detailing the communication plan for notifying personnel about the findings and individual results. 1981 AR226-1598 n90m378X0on78Oyd4524Qk7Ew 6
This document reports the analysis of 41 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the results and sample identification from the gas chromatographic method used. 1981 AR226-1599 4aq0q345nn1Ed2zq000o9mq0Q 3
This document reports the analysis of 53 blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours & Company, detailing the concentrations found in each sample. 1981 AR226-1602 vV3GJYbxn4pqRNoK1XXnnE5RY 3
This document reports the analysis of 37 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the concentrations found in each sample. 1981 AR226-1603 oeRZMgYMG40YY5Jrv65ZO9k4r 3
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours, revealing various concentrations of PFOA in the samples analyzed between September 22 and October 5, 1981. 1981 AR226-1605 oeDRoEZV32dRw3KbnL8oQyygg 3
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, detailing the concentrations found in various samples collected in October 1981. 1981 AR226-1606 gQ2Jaz6gLbaMwRno9pvK4KGa 3
The document reports on a study of C-8 (PFOA) blood levels in eighteen females transferred out of the Teflon divisions at DuPont's Washington Works, indicating a statistically significant average decrease of 15% in blood C-8 levels over approximately 129 days. 1981 AR226-1607 J3y7MVJg7x3az8vZjpd0VQqYa 24
The document reports the analysis of 37 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the concentrations found in each sample. 1981 AR226-1608 1gZmvgwNdvX9G4mYM3LQzDY3X 3
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, detailing the concentrations found in the samples and the methodology used for the gas chromatographic analysis. 1981 AR226-1609 0J8eVX467y95Vab4Koq05v13R 2
The document outlines an experimental program at E. I. Du Pont de Nemours and Company to analyze blood samples for FC-143 among employees in Teflon areas and to conduct product analyses for FC-143 in Teflon products, ensuring consistent laboratory procedures for reliable results. 1981 AR226-1648 JwxLxgrNmwrbw6LrnGBkenLe 2
The document reports the analysis of TEFLON felt samples for residual C-8 fluorosurfactant, revealing that the unbleached XT-7700 contained 3.5 ppm and the bleached XT-7800 contained 0.7 ppm of equivalent C-8 APFC, with findings consistent with typical levels found in other fluoropolymer products. 1981 AR226-1649 gDaMB2BdYgXEyyR6XaDVQzgqQ 4
The document reports on the analytical research conducted by E.I. du Pont de Nemours & Company regarding the removal of FC-143, a perfluorinated compound, from Teflon products, indicating that approximately 30-35% can be extracted through aqueous methods, with higher removal rates observed in SM-3 regenerated yarn compared to SM-2. 1981 AR226-1650 Z4b7V0zGmVmnpN6eQ29Xv3Dzp 6
This is a correspondence from the Spruance Research Laboratory discussing the shipment of heat-treated Teflon and Kevlar yarn samples for evaluation, including observations on denier changes and potential issues with the materials. 1981 AR226-1652 3k11BwKk8XexdavNXnE87Xpn 2
The document details a two-year oral (diet) toxicity and carcinogenicity study of fluorochemical FC-1A3 conducted by Riker Laboratories, Inc. for 3M Company on rats from April 1981 to May 1983. 1981 AR226-0439 QgBORJJj2LoZ8dKM6j1V2kqV4 320
The document details a two-year oral toxicity and carcinogenicity study of the fluorochemical FC-143 conducted by Riker Laboratories, Inc. for 3M Company, focusing on its effects in rats. 1981 AR226-0440 qd83on93DE3NV6bV31LRQzoVK 314
The document outlines efforts by P. P. Burks to eliminate or control FC-143, a fluorocarbon surfactant supplied by 3M Company, due to its reported embryotoxic effects, detailing successful thermal treatment methods that removed detectable levels of FC-143 from Teflon and Kevlar yarns, while further investigations into the causes of packing failures and alternative removal methods are ongoing. 1981 AR226-1653 MMjd6OJvyr0Kbm6wjkYG6QoO9 2
The document discusses a study by S. S. Shelburne on the thermal treatment of FC-143 in Teflon products, revealing that decarboxylation occurs at elevated temperatures, producing byproducts that require mass spectrometry for identification. 1981 AR226-1655 YDbVp2rjGqXxQyJv6dpdb9E10 4
The document discusses the status and interim processes for controlling FC-143 exposure, detailing the feasibility of ion exchange technology for removing approximately 90% of FC-143, a perfluorinated compound, from dispersion after polymerization, with a focus on commercialization and safety measures. 1981 AR226-1656 RaG4m33mkGxo4QozMn5L2y5Q8 13
The document reports on the analysis of FC-143 levels in Teflon products by E. I. du Pont de Nemours & Company, revealing that thermal treatment at temperatures of 175°C or higher can effectively remove FC-143 sodium salt, primarily through decarboxylation, although this method may negatively impact product performance. 1981 AR226-1657 a48g1a8yyrGNzVkdbXqo244RX 2
The document outlines a study conducted by E.I. DuPont de Nemours & Co. on monitoring the levels of FC-143 (ammonium perfluorooctanoate) in the Teflon process due to potential teratogenicity concerns raised by 3M, with objectives including measuring personnel exposure and developing accurate detection methods. 1981 AR226-1658 qmkXmGe5rVnEwnbaRoE9OGXwM 29
The document reports on an oral teratology study of T-2998CoC, sponsored by 3M, which found that the compound did not exhibit embryotoxic or teratogenic effects in pregnant Sprague-Dawley rats, although it caused maternal toxicity at the highest dose. 1981 AR226-0463 k65wRZXoJ4v3LQw1v0gQqDmjV 40
The document details an oral rangefinder study conducted by 3M Commercial Chemical Division to determine the upper dose level of T-3141CoC in pregnant rabbits for a subsequent teratology study, with dosing administered during specific gestational days. 1981 AR226-0464 N2n8ykq1ZvYwdZZDoBpe457yQ 8
The document summarizes the results of health evaluations conducted in 1981 at the Chemolite plant, highlighting that 12% of employees had significant blood pressure elevations and elevated cholesterol levels, which may indicate potential health risks related to exposure to perfluorinated compounds. 1981 AR226-0481 VjpgzeME3MLY4poaa6b7VLgOg 3
The document presents a calculation of the octanol/water partition coefficient for perfluorooctanoic acid, ammonium salt (FC-143), conducted by 3M Company, indicating a logP0w of approximately -0.9, which corresponds to a partition coefficient of about 0.126. 1981 AR226-0493 zzLoObL9M0XrRMnGG4NkdV21B 2
This document details a 1981 acute static toxicity study of perfluorooctanoic acid ammonium salt (PFOA ammonium salt) on the aquatic plant species Selenastrum capricornutum, conducted by the USEPA, which involved various test concentrations and analytical monitoring of algal cell counts and dry weights. 1981 AR226-0506 k9m1QwR3Xm82RZB3a72oG0wYq 20
An industrial hygiene investigation at the incinerator found that personal exposures to C-8 (perfluorooctanoic acid) were essentially zero and below the acceptable exposure limit, leading to the conclusion that no restrictions on personnel were necessary, while ruling out the incinerator as a source of C-8 emissions. 1981 AR226-1981 QMEY5EVmbq22YjvmnnNyNMwVk 2